WS #8652

The dominant narrative remains the Israel-Lebanon conflict and Iran-US nuclear talks, with no material de-escalation. Israeli forces have pushed past the Litani River into Lebanon, with heavy airstrikes on Tyre, escalating the conflict. Iran-US talks show no breakthrough, with Iran's chief negotiator stating 'US cannot be trusted' and Trump tightening terms. The Strait of Hormuz remains blocked, with Polymarket odds for normal traffic by end of May at 5.5% YES, down from 8%. Ukraine struck a Rosneft refinery in Saratov, 700km from the front line, confirmed by Zelenskyy and multiple sources. The S&P 500 hit four straight all-time highs, up 22% YTD, but AI-fueled chip rally sparks bubble debate. Arm CEO Rene Haas is in line for a billion-dollar payday if valuation targets are met. OpenAI's Greg Brockman steps out of shadows as IPO nears. No counter-signals to the prevailing bearish geopolitical thesis were detected. However, a new signal emerged: Revolution Medicines (RVMD) reported a Phase 3 win in pancreatic cancer, which could move the stock. Also, the US extended the deadline for Lukoil asset sales to June 27, which may affect energy markets. The S&P 500's continued rally and tech outperformance (DELL +17% AH, NVDA $81.6B revenue run-rate) suggest a structural capital vacuum favoring tech over defensives.